SynthesisCancer control : journal of the Moffitt Cancer Center
Effect of RAS Pathway Gene Mutations on Survival in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
Synthesis in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionMyelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenia, and risk of progression to acute myeloid leukemia. Somatic mutations in RAS pathway, including NRAS, KRAS, and PTPN11, are known contributors to leukemogenesis, yet their prognostic significance in MDS remains incompletely defined. This systematic review and meta-analysis assesses the impact of RAS pathway genes mutation on survival outcomes in adult patients with MDS.MethodsPubMed, Embase, Scopus, Web of Science, and Gene Expression Omnibus were systematically searched on January 2025. This review included English-language studies involving adults with MDS that examined the impact of RAS pathway mutations on survival, including either hazard ratios or Kaplan-Meier data. Studies were excluded if they included only specific treatments, narrow subgroups, secondary MDS, or were not original research. Sixteen papers eventually met the inclusion criteria. Data extraction and quality assessment were independently performed by multiple reviewers. The methodological quality of each study was assessed using the MASTER scale. Hazard ratios were pooled using a random-effects model.ResultsSixteen retrospective cohort studies involving 7969 patients tested for RAS pathway mutations were included. KRAS mutations were associated with poorer overall survival when compared to patients without the mutation (HR 1.66, 95% CI 1.32-2.08,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.